SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

On November 2021, 4chan created a female alternative to Wojak/PePe called “GleGle.”

glegle

GLEGLE is capturing significant community attention as investors rally behind its steady price action and potential for rapid growth within the memecoin sector. Enthusiasts are actively coordinating buying efforts and promoting the token's technical structure to drive momentum and visibility across decentralized exchanges.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating intense buzz following the announcement of positive 40-week Phase 3 results, which are fueling investor confidence in the sonelokimab nanobody platform. The community is actively debating the potential for an imminent buyout as the company prepares for an upcoming BLA submission, with many investors focusing on these clinical milestones as a key catalyst to drive the stock toward its previous valuation peaks.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending following a regulatory filing indicating that Berkshire Hathaway may offload its entire 27.5% stake in the company. While the news triggered a sharp sell-off as investors fear potential liquidation overhang, many in the community are debating whether the decline represents a deep-value buying opportunity given the company's 7% dividend yield and ongoing corporate restructuring efforts.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Canton is gaining traction as investors track its institutional integration and recent partnerships with major financial entities, fueling significant community excitement and speculation about its role in the future of tokenized assets. Enthusiasts are actively discussing the project's validator-locked supply and long-term potential, frequently comparing its growth trajectory to other established digital assets.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is gaining significant community traction as a meme-driven "Resist & Retire" movement that seeks to mock the traditional, often-criticized retirement savings system. The community is actively promoting its narrative across social platforms, fueled by high-energy engagement, recent exchange listings, and a shared sentiment that the current financial model is rigged against the average worker.

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment provides scanning devices, clinical applications, service capabilities, and digital solutions. The AVS segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The PCS segment specializes in providing medical devices, consumables, services, and digital solutions. The PDx segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded in 1892. It was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare Technologies Inc

GE HealthCare is capturing investor attention following a series of strategic AI-driven collaborations and positive earnings momentum that have strengthened its market position. The community is actively discussing the company's long-term growth potential and its evolving role in the AI-integrated medical imaging sector.

FLOKI is a community-driven, multi-chain utility token that powers a broad ecosystem including decentralized gaming, finance, and educational platforms. Originally evolving from a meme-based asset, the project now focuses on a utility-driven model centered around three pillars: community engagement, technical utility, and global charity work, balancing this ecosystem growth with social impact, such as building schools in developing nations like Ghana and Nigeria.  Key features include Valhalla, an NFT metaverse game where the token serves as the primary currency for capturing creatures and upgrading characters. The ecosystem also features the FlokiFi Locker for securing digital assets and the University of FLOKI for web3 education,with real-world integration facilitated through a prepaid debit card for everyday purchases at global stores. Staking FLOKI allows users to earn rewards in a sister token.  The project is led by a group of core advisors known by pseudonyms such as Sabre and B (The Viking) and is officially backed by DWF Labs, a major digital asset investment firm and market maker. While a small tax on decentralized trades helps fund development, value moves through the system as users utilize the token to pay for in-game items, access asset-locking services, or purchase merchandise.

Floki Token

Floki is experiencing a mix of community-driven speculation and institutional interest as investors track its potential to complete a market-leading "trilogy" alongside major meme coins. Sentiment is currently divided, with bulls pointing to the token's ecosystem expansion and European ETP legitimacy as catalysts for a potential reversal, while others express frustration over recent price volatility.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.&nbsp;  The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.&nbsp;  Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.&nbsp;  Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network continues to drive intense debate within the crypto community, with some users remaining optimistic about long-term ecosystem development while others express deep frustration over KYC delays and restricted access to unverified balances. While sentiment remains sharply divided between those viewing the project as a speculative long-term hold and those labeling it an advertising-driven scheme, the conversation is largely anchored in speculation regarding future exchange listings and roadmap milestones.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is currently a focal point for investors as it rides the momentum of a recent Japan PMDA regulatory approval, which validates its Alpha DaRT technology and serves as a major de-risking milestone. The community is actively discussing the stock's significant institutional buying, upcoming clinical trial readouts, and the potential for a breakout as the company advances its multi-indication oncology platform.

Chemtrade Logistics Income Fund engages in the provision of portfolio of industrial chemicals and value-added services. It operates through the following segments: Sulphur and Water Chemicals (SWC), Electrochemicals (EC), and Corporate. The SWC segment markets sulphuric acid, liquid sulphur dioxide, sulphur, sodium hydrosulphite, sodium bisulphate, zinc oxide, and a variety of inorganic coagulants used in water treatment. The EC segment manufactures and markets sodium chlorate and chlor-alkali products largely for the pulp and paper, oil and gas, and water treatment industries. The Corporate segment provides centralized services such as treasury, finance, information systems, human resources, legal and risk management, environmental, health, and safety support. The company was founded on May 17, 2001 and is headquartered in Toronto, Canada.

Chemtrade Logistics Income Fund - Unit

Chemtrade Logistics is trending as investors highlight its role as a potential beneficiary of increased North American semiconductor manufacturing and a tight global supply of sulphur. The community is actively discussing the company's robust free cash flow, share repurchase activity, and recent distribution increases, while monitoring potential regulatory developments regarding its North Vancouver facility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright

HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High Following Analyst Upgrade...

<ul class="summary-bullets"><li>Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701, the analyst said.&nbsp;</li><li>Clear sees ELVN-001 as a lower-risk, high-upside asset.</li><li>The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation.</li></ul>Shares of Enliven Therapeutics Inc (ELVN) rallied 15% on Wednesday after Wall Street highlighted that Merck's (MRK) $6.7 billion acquisition of Terns Pharmaceuticals' (TERN) TERN-701 underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies, similar to the kind Enliven is developing.Clear Street noted the opportunity for CML therapies despite generics. The acquisition signals growing interest in CML beyond Novartis (NVS), it added. Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.In this context, Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701 and multiple strategic paths to value, the firm argued.Clear sees ELVN-001 as a lower-risk, high-upside asset. The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation, pending U.S. Food and Drug Administration’s alignment on dose selection and trial design.<h2 class="st-heading-2">Merck-Terns Deal</h2>Merck said earlier on Wednesday that it has entered into a definitive agreement to acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion in a bid to add TERN-701 to its portfolio. TERN-701 is an experimental therapy currently in development for certain patients with CML. The transaction is expected to close in the second quarter of 2026, the company said, but analysts including RBC Capital and William Blair noted that it expects another bidder to emerge for Terns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ELVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ELVN">ELVN stock</a> has gained 68% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/salesforce-reportedly-holding-back-on-raises-for-higher-level-employees/cZ3YDSyRISD">Salesforce Reportedly Holding Back On Raises For Higher-Level Employees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Enliven Therapeutics, Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.

Equity

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.


Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade...

Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00

Mizuho upped their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High - Should You Buy?

Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High - Should You Buy...

Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% Higher - Here's What Happened

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 5.3% - Still a Buy...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are covering the firm, MarketBeat reports. One...

Enliven Therapeutics, Inc. $ELVN Shares Bought by HighVista Strategies LLC

HighVista Strategies LLC grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 83.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The...

Enliven Therapeutics (NASDAQ:ELVN) CFO Sells 10,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 10,000 shares of the company's stock in a transaction that occurred on Friday, March 6th. The shares were sold at an...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Enliven Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.46	--	--	N/A
Q4 '25	-$0.38	-$0.48	-24.68%	MISSED
Q3 '25	-$0.43	-$0.32	26.15%	BEAT
Q2 '25	-$0.54	-$0.49	8.72%	BEAT
Q1 '25	-$0.50	-$0.57	-13.66%	MISSED

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ELVN News

ELVNEnliven Therapeutics Inc